1
|
Netzer NC, Jaekel H, Popp R, Gostner JM, Decker M, Eisendle F, Turner R, Netzer P, Patzelt C, Steurer C, Cavalli M, Forstner F, Pramsohler S. Oxidative Stress Reaction to Hypobaric-Hyperoxic Civilian Flight Conditions. Biomolecules 2024; 14:481. [PMID: 38672497 PMCID: PMC11048003 DOI: 10.3390/biom14040481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 03/27/2024] [Accepted: 04/07/2024] [Indexed: 04/28/2024] Open
Abstract
BACKGROUND In military flight operations, during flights, fighter pilots constantly work under hyperoxic breathing conditions with supplemental oxygen in varying hypobaric environments. These conditions are suspected to cause oxidative stress to neuronal organ tissues. For civilian flight operations, the Federal Aviation Administration (FAA) also recommends supplemental oxygen for flying under hypobaric conditions equivalent to higher than 3048 m altitude, and has made it mandatory for conditions equivalent to more than 3657 m altitude. AIM We hypothesized that hypobaric-hyperoxic civilian commercial and private flight conditions with supplemental oxygen in a flight simulation in a hypobaric chamber at 2500 m and 4500 m equivalent altitude would cause significant oxidative stress in healthy individuals. METHODS Twelve healthy, COVID-19-vaccinated (third portion of vaccination 15 months before study onset) subjects (six male, six female, mean age 35.7 years) from a larger cohort were selected to perform a 3 h flight simulation in a hypobaric chamber with increasing supplemental oxygen levels (35%, 50%, 60%, and 100% fraction of inspired oxygen, FiO2, via venturi valve-equipped face mask), switching back and forth between simulated altitudes of 2500 m and 4500 m. Arterial blood pressure and oxygen saturation were constantly measured via radial catheter and blood samples for blood gases taken from the catheter at each altitude and oxygen level. Additional blood samples from the arterial catheter at baseline and 60% oxygen at both altitudes were centrifuged inside the chamber and the serum was frozen instantly at -21 °C for later analysis of the oxidative stress markers malondialdehyde low-density lipoprotein (M-LDL) and glutathione-peroxidase 1 (GPX1) via the ELISA test. RESULTS Eleven subjects finished the study without adverse events. Whereas the partial pressure of oxygen (PO2) levels increased in the mean with increasing oxygen levels from baseline 96.2 mm mercury (mmHg) to 160.9 mmHg at 2500 m altitude and 60% FiO2 and 113.2 mmHg at 4500 m altitude and 60% FiO2, there was no significant increase in both oxidative markers from baseline to 60% FiO2 at these simulated altitudes. Some individuals had a slight increase, whereas some showed no increase at all or even a slight decrease. A moderate correlation (Pearson correlation coefficient 0.55) existed between subject age and glutathione peroxidase levels at 60% FiO2 at 4500 m altitude. CONCLUSION Supplemental oxygen of 60% FiO2 in a flight simulation, compared to flying in cabin pressure levels equivalent to 2500 m-4500 m altitude, does not lead to a significant increase or decrease in the oxidative stress markers M-LDL and GPX1 in the serum of arterial blood.
Collapse
Affiliation(s)
- Nikolaus C. Netzer
- Institute of Mountain Emergency Medicine, Eurac Research, Noi Park Campus, Via Hypatia 2, 39100 Bozen, Italy; (F.E.); (R.T.)
- Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Department Psychology and Sport Science, University Innsbruck, 6020 Innsbruck, Austria; (P.N.); (S.P.)
- Division Sports Medicine and Rehabilitation, Department Internal Medicine, University Hospitals, 89070 Ulm, Germany
- Terra X Cube, Eurac Research, 39100 Bozen, Italy; (C.P.); (C.S.); (F.F.)
| | - Heidelinde Jaekel
- Institute of Medical Biochemistry, Medical University of Innsbruck, 6020 Innsbruck, Austria; (H.J.); (J.M.G.)
| | - Roland Popp
- Sleep Medicine Work Group, Department Psychiatry and Psychotherapy, University Hospitals, University Regensburg, 93053 Regensburg, Germany;
| | - Johanna M. Gostner
- Institute of Medical Biochemistry, Medical University of Innsbruck, 6020 Innsbruck, Austria; (H.J.); (J.M.G.)
| | - Michael Decker
- Institute for Aerospace Physiology, Department Physiology, Medical School, Case Western Reserve University, Cleveland, OH 44120, USA;
| | - Frederik Eisendle
- Institute of Mountain Emergency Medicine, Eurac Research, Noi Park Campus, Via Hypatia 2, 39100 Bozen, Italy; (F.E.); (R.T.)
| | - Rachel Turner
- Institute of Mountain Emergency Medicine, Eurac Research, Noi Park Campus, Via Hypatia 2, 39100 Bozen, Italy; (F.E.); (R.T.)
| | - Petra Netzer
- Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Department Psychology and Sport Science, University Innsbruck, 6020 Innsbruck, Austria; (P.N.); (S.P.)
| | - Carsten Patzelt
- Terra X Cube, Eurac Research, 39100 Bozen, Italy; (C.P.); (C.S.); (F.F.)
| | - Christian Steurer
- Terra X Cube, Eurac Research, 39100 Bozen, Italy; (C.P.); (C.S.); (F.F.)
| | - Marco Cavalli
- Terra X Cube, Eurac Research, 39100 Bozen, Italy; (C.P.); (C.S.); (F.F.)
| | - Florian Forstner
- Terra X Cube, Eurac Research, 39100 Bozen, Italy; (C.P.); (C.S.); (F.F.)
| | - Stephan Pramsohler
- Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Department Psychology and Sport Science, University Innsbruck, 6020 Innsbruck, Austria; (P.N.); (S.P.)
- Division Sports Medicine and Rehabilitation, Department Internal Medicine, University Hospitals, 89070 Ulm, Germany
| |
Collapse
|
2
|
Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR. Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Oncotarget 2018; 8:38251-38263. [PMID: 28418910 PMCID: PMC5503530 DOI: 10.18632/oncotarget.16368] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 02/27/2017] [Indexed: 01/01/2023] Open
Abstract
Breast cancer is a leading cause of cancer-related deaths. Anemia is common in breast cancer patients and can be treated with blood transfusions or with recombinant erythropoietin (EPO) to stimulate red blood cell production. Clinical studies have indicated decreased survival in some groups of cancer patients treated with EPO. Numerous tumor cells express the EPO receptor (EPOR), posing a risk that EPO treatment would enhance tumor growth, but the mechanisms involved in breast tumor progression are poorly understood. Here, we have examined the functional role of the EPO-EPOR axis in pre-clinical models of breast cancer. EPO induced the activation of PI3K/AKT and MAPK pathways in human breast cancer cell lines. EPOR knockdown abrogated human tumor cell growth, induced apoptosis through Bim, reduced invasiveness, and caused downregulation of MYC expression. EPO-induced MYC expression is mediated through the PI3K/AKT and MAPK pathways, and overexpression of MYC partially rescued loss of cell proliferation caused by EPOR downregulation. In a xenotransplantation model, designed to simulate recombinant EPO therapy in breast cancer patients, knockdown of EPOR markedly reduced tumor growth. Thus, our experiments in vitro and in vivo demonstrate that functional EPOR signaling is essential for the tumor-promoting effects of EPO and underline the importance of the EPO-EPOR axis in breast tumor progression.
Collapse
Affiliation(s)
- Ka Kui Chan
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.,Department of Pathology, The University of Hong Kong, Hong Kong Special Administrative Region 999077
| | - Kyle B Matchett
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK
| | | | - Hiu-Fung Yuen
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK
| | - Cian M McCrudden
- School of Pharmacy, Queen's University Belfast, Belfast BT9 7AE, UK
| | - Shu-Dong Zhang
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.,Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Londonderry, BT47 6SB, UK
| | - Gareth W Irwin
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK
| | - Matthew A Davidson
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK
| | - Thomas Rülicke
- Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna A-1210, Austria
| | - Sophie Schober
- Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna A-1210, Austria
| | - Ludger Hengst
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Innsbruck A-6020, Austria
| | - Heidelinde Jaekel
- Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Innsbruck A-6020, Austria
| | - Angela Platt-Higgins
- Institute of Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK
| | - Philip S Rudland
- Institute of Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK
| | - Ken I Mills
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK
| | - Perry Maxwell
- Northern Ireland Molecular Pathology Laboratory, Belfast Health & Social Care Trust, Queen's University Belfast, Belfast BT9 7AE, UK
| | - Mohamed El-Tanani
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.,Institute of Cancer Therapeutics, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
| | - Terence R Lappin
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK
| |
Collapse
|
3
|
Maxwell P, Melendez-Rodríguez F, Matchett KB, Aragones J, Ben-Califa N, Jaekel H, Hengst L, Lindner H, Bernardini A, Brockmeier U, Fandrey J, Grunert F, Oster HS, Mittelman M, El-Tanani M, Thiersch M, Schneider Gasser EM, Gassmann M, Dangoor D, Cuthbert RJ, Irvine A, Jordan A, Lappin T, Thompson J, Neumann D. Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation. Br J Haematol 2014; 168:429-42. [PMID: 25283956 DOI: 10.1111/bjh.13133] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Accepted: 08/02/2014] [Indexed: 12/12/2022]
Abstract
Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment.
Collapse
Affiliation(s)
- Perry Maxwell
- Northern Ireland Molecular Pathology Laboratory, Belfast Health & Social Care Trust, Queen's University Belfast, Belfast, UK; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Hernández P, Debray H, Jaekel H, Garfias Y, Jiménez Md MDC, Martínez-Cairo S, Zenteno E. Chemical characterization of the lectin from Amaranthus leucocarpus syn. hypocondriacus by 2-D proteome analysis. Glycoconj J 2001; 18:321-9. [PMID: 11788800 DOI: 10.1023/a:1013760915738] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In this work, we characterized chemically the N-acetyl-D-galactosamine specific lectin from Amaranthus leucocarpus syn hypocondriacus lectin (ALL). It is a dimeric glycoprotein composed by three isoforms with pl at 4.8, 4.9, and 5.2. Circular dichroism analysis indicated that the secondary structure of ALL contains 45% of \bibeta-sheet and 5% of \bialpha-helix. Amino acid sequence of the purified lectin and its isoforms was determined from peptides obtained after trypsin digestion by MALDI-TOF (Matrix assisted laser desorption ionization-time of flight). The tryptic peptides prepared from the purified lectin and the three isoforms showed different degrees (80 to 83%) of identity with the amino acid sequence belonging to a previously described high nutritional value protein from A. hypocondriacus not shown at the time to be a lectin. Furthermore, analysis of tryptic peptides obtained from ALL previously treated with peptide N-glycosidase, revealed a 93% identity with the aforementioned protein. Presence of N-glycosidically linked glycans of the oligomannosidic type and, in minor proportion, of the N-acetyllactosaminic type glycans was determined by affinity chromatography on immobilized Con A.
Collapse
Affiliation(s)
- P Hernández
- Departamento de Bioquímica, Instituto Nacional de Enfermedades Respiratorias, Tlalpan D.F., 14080, México
| | | | | | | | | | | | | |
Collapse
|
5
|
Jaekel H, Basler HD. [Behavior therapy with groups of normal-weight essential hypertension patients in general practice]. Psychother Psychosom Med Psychol 1985; 35:219-24. [PMID: 4034902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
6
|
Schüffel W, Jaekel H. Improvement of the physician's awareness of psychological problems of hypertensive patients. J Hypertens Suppl 1985; 3:S57-60. [PMID: 3870469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
7
|
Bolm G, Jaekel H, Holtschoppen U. [Group psychotherapy of dialysis patients (author's transl)]. Psychother Med Psychol (Stuttg) 1979; 29:105-12. [PMID: 451120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|